SMMT Q1 2021 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$192,000-40.7% YoY

Gross Profit

$192,000100.0% margin

Operating Income

-$17M-8814.1% margin

Net Income

-$17M-9108.3% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+3.8%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$21M

Stock-Based Comp.

$868,000

Balance Sheet

Total Assets

$141M

Total Liabilities

$76M

Stockholders' Equity

$64M

Cash & Equivalents

$102M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$192,000	$324,000	-40.7%
Gross Profit	$192,000	$386,291	-50.3%
Operating Income	-$17M	-$9M	-81.2%
Net Income	-$17M	-$6M	-185.1%

Revenue Segments

License and Service

$192,000100%

Geographic Segments

Latin America

$192,000100%